GlobeNewswire

Sky9 Capital Closes New Fund on $200 Million Hard Cap

Dela

HONG KONG, April 24, 2018 (GLOBE NEWSWIRE) -- Sky9 Capital announced today that it has completed the final closing of Sky9 Capital Fund III, L.P. with total capital commitments of $200 million.  With support from a strong group of world-class institutional investors, family foundations and entrepreneurs, the fund invests mainly in China-based businesses with a focus on early-stage companies in the internet, enterprise, and deep technology sectors.  Ron Cao, Founder & Managing Director, has over 18 years of extensive experience in venture capital and a track record of investing and growing successful China-based companies. 

The Sky9 team includes an experienced group of technologists, entrepreneurs and investors who have participated previously in the early-stage investments of some of the biggest technology companies in China including: DaVdian, eBroker, FaceU/Toutiao, FangDD, Innolight, Meituan/Dianping, ManBang Group, PPDai, PinDuoDuo, QingCloud, Rong360, Tujia, ZhaoYouWang and others.  With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, the firm has made a number of investments in the new fund including: ZhaoYouWang, the leading B2B e-commerce platform for the petroleum industry; eBroker, China's largest online marketplace for wealth management; Home, the leading social e-commerce platform for home furnishing; and Energy Monster, a power bank sharing platform.  Continuing its focus on early-stage and high-impact technology companies, Sky9 Capital invests between $1M to $10M in seed and Series A rounds, and $10M+ for expansion-stage companies.

"Sky9 has an exceptional team, and we have the experience and the commitment to continue to explore and invest in the biggest technology opportunities in China today," said Ron Cao. "The size and scale of the China internet and technology space continue to be unprecedented.  We are honored to have the chance to work with some extraordinary entrepreneurs in building exceptional companies together."

"Ron was a lead venture investor in the early-stage financing of our company," said Cliff Zhang, Co-founder & CEO of PPDai, a leading FinTech platform in China. "He has helped us tremendously over the years as we built out our business.  We look forward to our continued partnership with Sky9's new fund."  

"Sky9 Capital is eBroker's most important investor and partner," said Max He, Founder & CEO of eBroker, China's leading online wealth management platform. "In addition to providing advice and strategic planning, Sky9 focuses on building long-term value and is a true partner in growing together.  Congratulations to Ron and team for the successful fundraise."

For more information, please visit www.sky9capital.com.

About Sky9 Capital:

Sky9 Capital is a leading venture capital firm focused on investing in early-stage internet, enterprise and deep-tech start-ups in China. The firm invests with a systematic, analytical and conviction-based approach, focused on drawing deep market insights and discovering China's top talents. These principles guide our presence in Beijing, Shanghai, Shenzhen, and Silicon Valley as we support the innovators who will shape our future.  Through many years of cultivating deep relationships in the internet and technology sector and through its network of advisors, limited partners and strategic partners, the Sky9 team closely collaborates and shares resources with China's industry leaders like Baidu, Alibaba, Tencent, Toutiao, Meituan/Dianping, PinDuoDuo, Ctrip, PPDai, Rong360, Xiaomi and more.  For more information, please visit www.sky9capital.com.

Contact:

Cindy Chen
T: (86) 21 5238 3699
E: cindy@sky9capital.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/8118babc-12f8-4e57-8275-56eba9528a2d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum